Federal Employee Program BCBS (FEP)

How Federal Employee Program BCBS (FEP) approaches GLP-1 coverage

FEP BCBS operates three nationwide options (Standard, Basic, FEP Blue Focus) under the Federal Employees Health Benefits Program, regulated by OPM. Unlike Medicare Part D, FEHB plans are NOT bound by the statutory weight-loss-drug exclusion in Social Security Act §1860D-2(e)(2)(A), so FEP plans have discretion to include obesity medications on formulary. Recent benefit years have included T2D GLP-1s broadly and selected weight-management GLP-1s under prior authorization with BMI and comorbidity criteria — but specific drugs covered, tier placement, PA criteria, step therapy, and quantity limits change year-to-year and differ across the three FEP options. OPM has issued carrier letters encouraging (but not mandating) reasonable obesity-treatment coverage. Always check the current FEP formulary at fepblue.org for your specific plan option and benefit year, and verify with your specific plan and current formulary before assuming coverage.

Statutory and structural notes

FEP BCBS is a commercial-style FEHB plan regulated by OPM under 5 U.S.C. Chapter 89, not Medicare statute, so the Medicare Modernization Act 2003 / SSA §1860D-2(e)(2)(A) weight-loss-drug exclusion does NOT apply. ACA essential health benefits requirements also do not directly govern FEHB plans, so weight-loss-drug coverage is at the carrier's discretion within OPM guidance. The Treat and Reduce Obesity Act (TROA) remains a proposed bill not enacted as of 2026 and targets Medicare, not FEHB.

Typically considered for coverage

The list below reflects general patterns observed across Federal Employee Program BCBS (FEP)plan documents. Coverage for any specific drug, dose, or indication must be confirmed against your own plan's current formulary and medical policy.

• Ozempic (semaglutide) for type 2 diabetes with diabetes documentation — verify with your specific plan and current formulary
• Mounjaro (tirzepatide) for type 2 diabetes with diabetes documentation — verify with your specific plan and current formulary
• Rybelsus (oral semaglutide) for type 2 diabetes — verify with your specific plan and current formulary
• Trulicity (dulaglutide) for type 2 diabetes — verify with your specific plan and current formulary
• Wegovy (semaglutide) for chronic weight management under PA with BMI/comorbidity criteria, and potentially for cardiovascular risk reduction following the SELECT indication — verify with your specific plan and current formulary
• Zepbound (tirzepatide) for chronic weight management under PA, and potentially for obstructive sleep apnea following the 2024 OSA indication — verify with your specific plan and current formulary
• Saxenda (liraglutide) for weight management under PA in some plan options — verify with your specific plan and current formulary

Typically excluded

• Off-label weight-loss use of T2D-only GLP-1s (e.g., Ozempic, Mounjaro) without a diabetes diagnosis
• Compounded semaglutide/tirzepatide from 503A/503B facilities (generally not covered by commercial plans including FEP)
• Cosmetic or non-medical weight-loss use without documented BMI/comorbidity criteria
• GLP-1s prescribed without meeting plan-specific PA, step-therapy, or quantity-limit requirements
• Drugs filled outside the FEP pharmacy network when network use is required by the plan option

Prior authorization

Prior authorization is commonly required for GLP-1 medications under Federal Employee Program BCBS (FEP) plans. Your prescriber typically submits a PA form with diagnosis codes, lab results (e.g., A1c for T2D, BMI for weight management), documented prior therapy attempts, and clinical justification.

Appeal strategy if denied

Request written denial and PA criteria. File Level 1 internal appeal with a Letter of Medical Necessity (diagnosis, labs/BMI, comorbidities, prior failed therapies, FDA-indication match). If denied, request Level 2 reconsideration. FEP enrollees uniquely may request OPM review under 5 CFR Part 890 within 90 days of final carrier denial. Use peer-to-peer review for faster PA resolution; request expedited review for urgent cases.

GLP1Zoom is not an insurance company, broker, or health plan. We summarize general payer patterns from public plan documents and statute to help you ask the right questions. Always verify current coverage with your plan's member services. Full disclaimer.